KalVista Pharmaceuticals brings to Chiesi Group the product Ekterly, the first FDA-approved oral drug for acute treatment of swelling attacks from the rare disease hereditary angioedema. Ekterly’s tablet formulation offers a dosing edge compared to injectable HAE medications.

The post Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition appeared first on MedCity News.

Obsidian Therapeutics aims to show its TIL cell therapy has advantages over an Iovance Biotherapeutics TIL therapy marketed for treating melanoma. Obsidian’s merger with Galera Therapeutics will give it a public listing and a private placement to support clinical development of the combined company’s cancer drug pipeline.

The post Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials appeared first on MedCity News.

Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance.

The post Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors appeared first on MedCity News.

Gilead Sciences’ Tubulis acquisition brings antibody drug conjugates in clinical development for cancer. Analysts say the Tubulis platform technologies that yielded these ADCs could also help Gilead develop drugs in other therapeutic areas.

The post Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis appeared first on MedCity News.

Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease Prader-Willi syndrome. This blockbuster prospect complements Crenessity, a Neurocrine drug approved for treating a rare endocrine disorder called congenital adrenal hyperplasia.

The post Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug appeared first on MedCity News.

Biogen’s Apellis Pharmaceuticals acquisition comes nearly two years after the drugmaker purchased immunology startup Human Immunology Biosciences. CEO Chris Viehbacher said Apellis accelerates Biogen’s expansion in nephrology, supporting a HI-Bio drug currently in pivotal testing for three kidney conditions.

The post Why Biogen Is Paying $5.6B to Buy Apellis Pharma appeared first on MedCity News.

Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agonist drug developers that includes Takeda Pharmaceutical, Alkermes, and Eisai.

The post Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition appeared first on MedCity News.

Merck has been acquiring assets that could help make up for the coming revenue decline as its top product, the cancer drug Keytruda, drops off the patent cliff. Terns Pharmaceuticals’ lead product candidate, in development for treating a type of leukemia, could offer dosing and efficacy advantages over the Novartis drug Scemblix.

The post Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug appeared first on MedCity News.

Novartis already markets the PI3Kα inhibitor Piqray for breast cancer, but acquiring a Synnovation Therapeutics subsidiary brings an early clinical program that the pharma company claims could be best in the class of next-generation therapies for the target. Competitors include Eli Lilly, Relay Therapeutics, and OnKure Therapeutics.

The post Why Novartis Is Paying $2B for a Cancer Drug That Hits the Same Target as One of Its Own Products appeared first on MedCity News.

Sutter Health is acquiring Allina Health in a deal that would create a $26 billion nonprofit health system spanning California, Minnesota and Wisconsin. The deal reflects a broader wave of hospital consolidation as providers pursue scale to manage rising costs and fund tech investments.

The post Sutter, Allina Health Combine to Form $26B Health System appeared first on MedCity News.

Quantum Health acquired CirrusMD to add 24/7 physician chat to its healthcare navigation services and deliver faster clinical support.

The post Why Quantum Health Acquired Virtual Care Company CirrusMD appeared first on MedCity News.

Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children.

The post Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma appeared first on MedCity News.

Gilead Sciences and Arcellx have been collaborating on the multiple myeloma cell therapy anito-cel since 2022. This therapy was designed to provide better safety, which would be an advantage over Carvykti, the blockbuster multiple myeloma product marketed by Johnson & Johnson and Legend Biotech.

The post Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B Deal appeared first on MedCity News.

Experts say Hims & Hers’ acquisition of Eucalyptus positions the company for global expansion and revenue diversification amid U.S. GLP-1 regulatory challenges.

The post What Experts Say About Hims & Hers’ $1.15B Acquisition of Eucalyptus appeared first on MedCity News.

Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by AstraZeneca, AbbVie, Gilead Sciences, and Bristol Myers Squibb.

The post Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B appeared first on MedCity News.

Digital health is entering a more mature phase in 2026 as consolidation accelerates through targeted M&A, driven by the need for scale, artificial intelligence and pressure from payers, investors say.

The post The Digital Health M&A Wave Is Finally Here appeared first on MedCity News.

This is Wisp’s first acquisition, for which the terms of the deal were not disclosed. It allows the company to expand into providing in-person care to complement its virtual support.

The post Wisp Acquires Sexual Health Platform TBD Health appeared first on MedCity News.

The contract research organization consolidation trend continues with Worldwide Clinical Trials striking a deal for Catalyst Clinical Research, which has particular expertise in oncology. Worldwide is a portfolio company of Kohlberg, a private equity firm.

The post Worldwide Clinical Trials to Buy Catalyst, Another M&A Deal Between Private Equity-Backed CROs appeared first on MedCity News.

Rapt Therapeutics brings to GSK ozureprubart, a long-acting antibody that inhibits the validated immunology target immunoglobulin E (IgE). If GSK is able to bring this drug to the market, it would complete with the blockbuster Genentech and Novartis allergy drug Xolair.

The post GSK Grows in Immunology, Buying Rapt Therapeutics and Food Allergy Drug in $2.2B Deal appeared first on MedCity News.

Ventyx Biosciences’ lead program, an oral small molecule inhibitor of NLRP3, has encouraging clinical data from separate mid-stage tests in cardiovascular disease and Parkinson’s disease. Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity.

The post Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition appeared first on MedCity News.

Obesity and diabetes drug R&D partnerships struck in 2025 represented $20.2 billion in total deal value, a new record high, according to a new report from J.P. Morgan. While IPO activity and venture investment trended downward, M&A activity was significantly higher.

The post J.P. Morgan Report: Obesity & Diabetes Dealmaking Set a New Record in 2025 appeared first on MedCity News.

Dynavax Technologies brings Sanofi a commercialized hepatitis B vaccine and a clinical-stage shingles vaccine, both of which offer differentiation from products marketed by GSK. It’s Sanofi’s second billion-dollar vaccines acquisition of 2025.

The post Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition appeared first on MedCity News.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics is a marriage of two rare disease biotech companies. Amicus’s two commercialized products, for the enzyme deficiencies Fabry disease and Pompe disease, are each projected to become blockbuster sellers.

The post BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition appeared first on MedCity News.

Arthrosi Therapeutics’ pozdeutinurad is in Phase 3 testing as a treatment for uncontrolled gout. Sobi says this once-daily capsule complements its own asset, an infused biologic medicine currently under FDA review as a third-line gout treatment.

The post Sobi Grows Its Gout Drug Prospects With $950M Acquisition of Startup Arthrosi Therapeutics appeared first on MedCity News.

Merck’s Cidara Therapeutics acquisition brings a lead program with potential to become a first-in-class drug for preventing influenza infection. A Phase 3 study is already underway, timed to coincide with the start of the flu season in the Northern Hemisphere.

The post Merck Makes Big Antiviral Move With $9B Deal to Land Cidara’s Late-Stage Drug for Flu Prevention appeared first on MedCity News.

Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favor, ending a bidding war for Metsera and its next-generation obesity medications.

The post Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera appeared first on MedCity News.

Pfizer claims Metsera breached their merger agreement, adding that a tie-up of the biotech with GLP-1 drug giant Novo Nordisk would violate U.S. antitrust law. Metsera called the arguments “nonsense” and said Pfizer is trying to buy the obesity drug developer for less than what Novo is willing to pay.

The post Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal appeared first on MedCity News.

Private equity-backed Clario brings to Thermo Fisher Scientific software that collects, manages, and analyzes clinical trial endpoint data. Analysts see Clario’s offerings as highly complementary to PPD, the contract research organization that Thermo Fisher acquired in 2021.

The post Thermo Fisher Expands Biopharma Offerings With $9B Deal for Clinical Trial Software Firm Clario appeared first on MedCity News.

Acquisition talks for Metsera that played out this year culminated in an agreement with Pfizer, which agreed to buy the obesity drug developer for $4.9 billion. Novo Nordisk, a finalist in that pursuit, is positioning itself as a deal spoiler with a new unsolicited offer that shells out much more upfront cash.

The post Novo Nordisk Swoops In With $6.5B Bid to Top Pfizer’s M&A Deal With Obesity Biotech Metsera appeared first on MedCity News.

Avidity Biosciences brings to Novartis three RNA therapies in pivotal testing for rare neuromuscular diseases along with the technology that produced them. This platform develops drugs in a new class of targeted medicines offering potential to expand the delivery of RNA treatments beyond the liver.

The post Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition appeared first on MedCity News.